Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

Overview of attention for article published in The Lancet, June 2011

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 3 news outlets
blogs: 1 blog
policy: 1 policy source
twitter: 19 X users

patent: 30 patents
facebook: 1 Facebook page
f1000: 1 research highlight platform
guideline: 2 clinical guideline sources

Readers on

mendeley: 327 Mendeley
citeulike: 1 CiteULike
connotea: 1 Connotea

So far, Altmetric has seen 3 news stories from 3 outlets.

Teplizumab in Type 1 Diabetes Mellitus: An Updated Review

Touch ENDOCRINOLOGY, 05 Oct 2023

1. DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet. 2018;391:2449–62.

T-cell analysis may predict immunotherapy response in type 1 diabetes

medwireNews, 17 Aug 2020

17-08-2020 | Diabetes | News | Article medwireNews: Analysis of pretreatment follicular helper T (TFH) cell subpopulations…

Abatacept vs Anti-TNF: Lower Diabetes Risk in RA?

MedPage Today, 15 Apr 2020

Rheumatology > Arthritis Risks with adalimumab and infliximab doubled in large cohort study, but "causal conclusion" unclear…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.